WeVote
Log In

Bill

Bill

HR 9169

PKD Cures Act

119th Congress Introduced by Don Bacon and 4 co-sponsors

The bill aims to boost PKD research through funding and interagency coordination, improving data, trials, and resources for researchers and patients.

Introduced in House
0
WeVote Research Nonpartisan
Bill Summary · HR 9169

Summary of HR 9169 (Session 119) – To support polycystic kidney disease research, and for other purposes

Purpose and intent

HR 9169 is a United States House of Representatives bill focused on advancing research related to polycystic kidney disease (PKD). The principal aim is to bolster efforts to understand, treat, and potentially cure PKD through targeted funding, programmatic coordination, and related activities. The bill’s sponsor and multiple co-sponsors indicate a bipartisan interest in accelerating PKD research and related policy measures.

Key provisions and changes

  • Research funding and support for PKD: The bill seeks to enhance federal support for PKD research. While the exact funding levels are not specified in the summary, the intent is typically to authorize appropriations or direct agencies to prioritize PKD-related projects.
  • Coordination among agencies: The measure commonly includes provisions to improve coordination across federal agencies (such as NIH and other relevant health or science bodies) to streamline PKD research efforts, reduce duplication, and accelerate progress.
  • Support for researchers and patients: Provisions may establish or expand programs that support PKD researchers, clinical trials, patient registries, and data sharing to improve study quality and accelerate translation from basic research to therapies.
  • Public awareness and education: The bill may include activities aimed at raising awareness of PKD, disseminating research findings, and informing patients and clinicians about advances and available resources.
  • Authorization and oversight: It would typically set out reporting requirements or oversight mechanisms to monitor the use of funds and the progress of PKD initiatives, ensuring accountability and alignment with congressional intent.

Who or what would be affected

  • Researchers and academic institutions engaged in PKD research would have potential access to increased funding, collaboration opportunities, and data resources.
  • Federal health and science agencies (e.g., National Institutes of Health and related entities) would implement the programmatic priorities, funding allocations, and interagency coordination mandated by the bill.
  • PKD patients and patient advocacy groups could benefit from enhanced research activity, better information, and possibly faster development of treatments.
  • Clinical trial infrastructure and registries may expand or receive support to improve PKD trial recruitment, data collection, and analysis.

Procedural and timeline considerations

  • Introduced and referral: The bill was introduced in the House and referred to the House Committee on Energy and Commerce (June 4, 2026). This committee will review, amend, and potentially advance the bill toward floor consideration.
  • Next steps in the legislative process: Following committee action, the bill would typically proceed to full House consideration, then to the Senate (where similar or companion legislation would be considered). If enacted, it would require presidential signing to become law.
  • Potential for amendments: As a science/health policy bill, amendments could address funding levels, scope of PKD programs, or interagency responsibilities before any final passage.

This summary captures the bill’s stated focus on PKD research, anticipated mechanisms (funding, coordination, and oversight), and its potential impact on researchers, agencies, and patients, based on the information available. If you have access to the bill’s text, I can provide a more detailed, line-by-line breakdown of specific sections and any numerical funding figures or established programs.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.